ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
William J. Anderson
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lackey, V. L.
Right arrow Articles by Anderson, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lackey, V. L.
Right arrow Articles by Anderson, W. J.

Ann Thorac Surg 1989;48:218-221
© 1989 The Society of Thoracic Surgeons

Articles

Neoadjuvant therapy of squamous cell carcinoma of the esophagus: Role of resection and benefit in partial responders

Van L. Lackey, MD, Morris T. Reagan, MD, R.Arnold Smith, MD, William J. Anderson, MD*

Deparments of Surgery, Oncology, and Radiation Therapy, Mississippi Baptist Medical Center and St. Dominic's Hospital, Jackson, Mssissippi USA

* Address reprint requests to Dr Anderson, Suite 404, Medical Plaza Building, 2011 Church St, Nashville, TN 37203.

Twenty-eight patients were treated between 1981 and 1987 with a combination of radiation therapy and two courses of 5-fluorouracil and cisplatin followed by esophageal resection. Sixteen patients (57%) underwent resection. Operative mortality was 6% (1 of 16), and the 15 operative survivors have been followed for more than 23 months. Complete pathological response was achieved in 8 of the 15 patients, and 10 patients (66%) are alive with no evidence of disease; 4 patients (27%) have survived with no evidence of disease for more than 5 years. Four partial responders are alive, and 3 are alive with no evidence of disease for more than 5 years. An aggressive approach with a low mortality has demonstrated survival benefit to complete responders and, contrary to findings of previous reports, has established a role for surgical resection and survival benefit in patients with partial response, with 3 of 7 (47%) patients surviving more than 5 years.




This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
A. Imdahl, G. Bognar, J. Schulte-Monting, U. Schoffel, E. H. Farthmann, and C. Ihling
Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer
Eur J Cardiothorac Surg, April 1, 2002; 21(4): 657 - 663.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1989 by The Society of Thoracic Surgeons.